Trial · NCT06956170
Outcomes29
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 20 of 29
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-Free Survival (PFS) | Up to approximately 120 weeks | Intent-to-Treat (ITT) Population included all randomized participants whether or not randomized treatment was administered. | Months | MEDIAN |
| SECONDARY | Overall Survival (OS) | Up to approximately 407 weeks | |||
| SECONDARY | Duration of Response (DoR) | Up to approximately 407 weeks | |||
| SECONDARY | Minimal Residual Disease (MRD) Negativity Rate | Up to approximately 407 weeks | |||
| SECONDARY | Overall Response Rate (ORR) | Up to approximately 407 weeks | |||
| SECONDARY | Complete Response Rate (CRR) | Up to approximately 407 weeks | |||
| SECONDARY | Percentage of Participants With a Confirmed Very Good Partial Response (VGPR) or Better | Up to approximately 407 weeks | |||
| SECONDARY | Time to Best Response (TTBR) | Up to approximately 407 weeks | |||
| SECONDARY | Time to Response (TTR) | Up to approximately 407 weeks | |||
| SECONDARY | Time to Progression (TTP) | Up to approximately 407 weeks | |||
| SECONDARY | Progression-free Survival on Subsequent Line of Therapy (PFS2) | Up to approximately 407 weeks | |||
| SECONDARY | Number of Participants With Adverse Events (AEs) | Up to approximately 407 weeks | |||
| SECONDARY | Number of Participants With Clinically Significant Changes in Hematology Parameters | Up to approximately 407 weeks | |||
| SECONDARY | Number of Participants With Clinically Significant Changes in Clinical Chemistry Parameters | Up to approximately 407 weeks | |||
| SECONDARY | Number of Participants With Abnormal Ocular Findings on Ophthalmic Examination | Up to approximately 407 weeks | |||
| SECONDARY | Plasma Concentrations of Belantamab Mafodotin (ADC) | Up to approximately 407 weeks | |||
| SECONDARY | Plasma Concentrations of Monomethyl Auristatin-F With a Cysteine Linker (Cys-mcMMAF) | Up to approximately 407 weeks | |||
| SECONDARY | Area Under Plasma Concentration-time Curve (AUC) From Time 0 to the Time of the Last Quantifiable Concentration (C(Tlast)) [AUC (0-last)] for Pomalidomide | Up to approximately 407 weeks | |||
| SECONDARY | Area Under Plasma Concentration-time Curve (AUC) From Time 0 to End of the Dosing Interval [AUC (0-tau)] for Pomalidomide | Up to approximately 407 weeks | |||
| SECONDARY | Maximum Concentration (Cmax) for Pomalidomide | Up to approximately 407 weeks |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06956170/outcomes